FDA Warning Letter: Children's Growth Supplement Contains Undeclared Drug Ingredient
On December 19, 2025, the FDA issued a warning letter to Agebox Inc. for marketing children's growth supplements containing undeclared ibutamoren mesylate (MK-677), a growth hormone secretagogue that has never been approved by FDA for any use. The products, marketed as "iKids-Growth IGF-1 Support Day Formula" and "iKids-Growth IGF-1 Support Night Formula," were sold as dietary supplements but contained an ingredient that is explicitly excluded from the dietary supplement definition.
What Happened
FDA's laboratory analysis confirmed that both iKids-Growth products contained ibutamoren mesylate, which was not disclosed anywhere on the product labels. Parents were unknowingly giving their children a pharmaceutical ingredient with documented side effects including increased appetite, water retention, fatigue, alterations in glucose metabolism, and potential increased risk of congestive heart failure.
The company marketed these products directly to parents through their website (agebox.com) and Facebook, making explicit growth and height claims:
"Will iKids-Growth help my kid grow taller? Yes."
"Helps the liver respond better to growth hormone, increasing IGF-1 production"
"This process effectively regulates and increases height growth"
Key Violations
FDA identified four major violations in the warning letter (CMS # 718252):
Unapproved New Drugs (21 U.S.C. § 355(a)): Products containing ibutamoren are unapproved new drugs because the ingredient is not generally recognized as safe and effective (GRAS/E) and has no approved New Drug Application (NDA).
Misbranded Drugs (21 U.S.C. § 352(a)): Product labels failed to disclose the presence of ibutamoren mesylate, rendering the labeling false and misleading. This violation is particularly serious because parents couldn't make informed decisions about potential health risks or dangerous drug interactions.
Excluded from Dietary Supplement Definition (21 U.S.C. § 321(ff)(3)(B)(ii)): Ibutamoren was the subject of substantial clinical investigations as a new drug before being marketed as a dietary supplement ingredient. FDA cited published clinical studies from 1996 and 2001 demonstrating drug investigation status, which excludes ibutamoren from the dietary supplement definition.
Unapproved Drug Claims: Marketing claims established drug intent by asserting the products increase height, boost IGF-1 levels, and affect the GH-IGF-1 axis—claims that go far beyond permissible structure/function claims for dietary supplements.
Why This Matters for Your Brand
This enforcement action represents FDA's continued crackdown on supplement products containing undeclared pharmaceutical ingredients, particularly when marketed to vulnerable populations like children. The warning letter demonstrates several critical enforcement trends:
Heightened scrutiny of growth and hormonal claims: Products making claims related to height, growth, or hormonal pathways—especially for children—receive immediate FDA attention and laboratory testing.
Zero tolerance for undeclared ingredients: Every ingredient must be accurately disclosed on labels. The presence of undeclared active pharmaceutical ingredients (APIs) is a per se violation that triggers immediate enforcement.
Pediatric products face stricter enforcement: Any safety risk to minors triggers swift FDA action, including warning letters issued before import alerts or seizures.
Laboratory verification is increasing: FDA is actively testing products and verifying ingredient identity, not relying solely on label claims or certificates of analysis from manufacturers.
What This Means for Importers and Formulators
If you formulate or import supplements—particularly those targeting growth, performance, or hormonal effects—you must:
Verify every ingredient through independent third-party testing
Research whether ingredients have been investigated as drugs (check FDA clinical trials database)
Ensure all ingredients are properly disclosed on labels
Avoid growth, height, or hormonal claims for children's products
Understand that "enhancing" or "supporting" IGF-1, growth hormone, or similar pathways likely establishes drug intent
The Agebox warning letter serves as a clear reminder that premium pricing, sophisticated marketing, or targeting health-conscious parents does not exempt products from fundamental FDA requirements. The consequences of non-compliance include warning letters, import detention, seizures, injunctions, and potential criminal prosecution.
Get the Full Enforcement Breakdown
Compliance Vault subscribers receive comprehensive analysis of every major FDA enforcement action, including:
✓ 15-page detailed breakdown with complete legal citations and statutory references
✓ Prevention checklist specifically tailored to your product category
✓ Response strategies if you receive a warning letter
✓ Side-by-side violation analysis showing what the company did wrong and how to avoid it
✓ Industry impact assessment identifying who else is at risk
✓ Recommended actions with implementation timelines
The full Agebox enforcement breakdown includes detailed analysis of the clinical studies FDA cited, explanation of the dietary supplement exclusion provision, guidance on evaluating novel ingredients, and a complete prevention checklist for brands making growth or performance claims.
Related Topics: FDA Warning Letters, Dietary Supplements, Unapproved Drugs, Undeclared Ingredients, Children's Products, Growth Claims, Dietary Supplement Exclusions
Legal Citations:
FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1) - Definition of "drug"
FD&C Act § 201(ff)(3)(B)(ii), 21 U.S.C. § 321(ff)(3)(B)(ii) - Dietary supplement exclusions
FD&C Act § 301(d), 21 U.S.C. § 331(d) - Prohibited acts (unapproved new drugs)
FD&C Act § 502(a), 21 U.S.C. § 352(a) - Misbranding (false/misleading labeling)
FD&C Act § 505(a), 21 U.S.C. § 355(a) - New drug approval requirement
FDA Warning Letter Reference: CMS # 718252, December 19, 2025 Company: Agebox Inc., Wilmington, DE Issuing Office: Center for Drug Evaluation and Research (CDER)